Despite 70-Year Romance, Palimony Is Denied for Lack of Cohabitation

If you are having trouble viewing this message, please click here.

FDA Extends Meeting Date to March 7th & 8th!

Biogen Idec/Elan Tysabri Risk Assessment:

Will the Multiple Sclerosis Drug Return to Market?

Order Now and Save 30%!

Tune in live March 7-8th: FDA's Peripheral & Central Nervous System Drugs Advisory Committee will discuss adverse events reported with Biogen Idec/Elan's Tysabri and whether the multiple sclerosis drug is safe enough to return to market.

Does efficacy of natalizumab outweigh the risk of progressive multifocal leukoencephalopathy and serious infections?

At issue:

* Is Biogen Idec's risk management plan adequate?

* Are there tests that can detect patients at risk for PML prior to Tysabri treatment?

* What should Biogen Idec tell doctors in their proposed medical education program for Tysabri re-marketing?

REGISTER BEFORE FEBRUARY 24 AND SAVE 30%

Contact us and mention this email BEFORE FEB. 24 and receive a 30% discount on all broadcast services related to the March 7-8th meeting.

Call to register:

1-800-627-8171

* Live webcasts- right to your computer

* Videoconference- ideal for groups

* DVD and Videotape recordings- available next day

Call to register:

1-800-627-8171

CBS News-Health

Drug Maker Off Hook In Vioxx Case

USA Today-Health

Tests find bird flu in Egypt, France; U.N. worries of spread

New Brain Imaging Reveals Damage MRI Misses

Recalls, lawsuits make medical device merger hairy